ADVERTISEMENT

ADVERTISEMENT

Novo Nordisk agrees to cap insulin price, give drug for free to neediest Minnesotans

A settlement Monday means free insulin for Minnesotans at or below 400% of the poverty line and for an out-of-pocket cap of $35 per monthly prescription, regardless of insurance, when paid in cash

Insulin Vials File Photo.jpg
A collection of insulin vials. Insulin is an enzymatic injection that Type 1 and some Type 2 diabetics require on a daily basis to live.
Forum News Service file photo

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest insulin makers of charging astronomically high prices for the diabetes drug.

The settlement filed on Monday, Jan. 27 in the Newark, New Jersey federal court follows similar settlements last year with Eli Lilly and French drugmaker Sanofi.

ADVERTISEMENT

It requires Novo Nordisk to cap out-of-pocket costs for patients who pay with cash at $35 per monthly prescription, regardless of whether the patient has insurance.

Novo Nordisk will also provide free insulin to the neediest Minnesotans, defined as those with annual household incomes at or below 400% of the federal poverty level, equivalent to $128,600 for a family of four.

Keith Ellison speaks Friday at campaign rally at Denfeld High School in Duluth on July 13. Ellison is running for Minnesota Attorney General. Clint Austin / Forum News Service
Keith Ellison.
Forum News Service file photo

The Danish company denied wrongdoing in agreeing to the settlement, which lasts five years and requires court approval.

Eli Lilly and Sanofi settled with Minnesota Attorney General Keith Ellison in February 2024 and July 2024, respectively.

At a press conference, Ellison said the settlements reduce patients' insulin costs by more than 90%, ending many years when manufacturers prioritized "making billions and profits over saving lives."

A Novo Nordisk spokesperson said the drugmaker was pleased to settle, and that the accord reflected its commitment to ensuring affordable access to insulin. The company has U.S. offices in Plainsboro, New Jersey.

Ellison accused Novo Nordisk, Eli Lilly and Sanofi of inflating patients' out-of-pocket costs for insulin based on the wholesale acquisition cost, or list price, of the drug.

ADVERTISEMENT

The drugmakers were accused of setting artificially high list prices, only to then negotiate lower prices by paying rebates to pharmacy benefit managers.

Insulin is vital to control blood sugar in patients with type 1 diabetes, and is used by some patients with the more common type 2 diabetes.

Minnesota's case began in 2018 under Ellison's predecessor, Lori Swanson.

______________________________________________________

This story was written by one of our partner news agencies. Forum Communications Company uses content from agencies such as Reuters, Kaiser Health News, Tribune News Service and others to provide a wider range of news to our readers. Learn more about the news services FCC uses here.

Conversation

ADVERTISEMENT

What To Read Next
Get Local

ADVERTISEMENT